NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Thursday, February, 13th. The medical device company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.41. The medical device company earned $462.80 million during the quarter, compared to analyst estimates of $457 million. DexCom had a return on equity of 22.65% and a net margin of 6.85%. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for DexCom.

DexCom updated its FY 2020 After-Hours earnings guidance on Thursday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.725-1.775 billion, compared to the consensus revenue estimate of $1.77 billion.

18 analysts have issued 12-month price objectives for DexCom's stock. Their forecasts range from $125.00 to $300.00. On average, they anticipate DexCom's stock price to reach $256.72 in the next twelve months. This suggests that the stock has a possible downside of 9.6%. View Analyst Price Targets for DexCom.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

Media stories about DXCM stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DexCom earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for DexCom.

DexCom saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,750,000 shares, a decline of 5.4% from the January 15th total of 5,020,000 shares. Based on an average daily trading volume, of 986,900 shares, the short-interest ratio is currently 4.8 days. Currently, 5.3% of the shares of the company are short sold. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), ServiceNow (NOW), Home Depot (HD), Micron Technology (MU), Adobe (ADBE) and Veeva Systems (VEEV).

DexCom's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.26%), Jennison Associates LLC (3.78%), Artisan Partners Limited Partnership (2.06%), Blair William & Co. IL (1.32%), Fred Alger Management LLC (0.82%) and Renaissance Technologies LLC (0.77%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Peregrine Capital Management LLC, Columbus Circle Investors, First Trust Advisors LP, Point72 Asset Management L.P. and Artisan Partners Limited Partnership. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Fred Alger Management LLC, Beacon Investment Advisory Services Inc., Baird Financial Group Inc., Lord Abbett & CO. LLC, Kornitzer Capital Management Inc. KS, Cubist Systematic Strategies LLC and Blair William & Co. IL. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $283.91.

DexCom has a market capitalization of $26.00 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]